Pruriginosa Pattern of Dystrophic Epidermolisys Bullosa: Clinical Case
https://doi.org/10.15690/pf.v19i6.2476
Abstract
Background. Epidermolisys bullosa pruriginosa is a rare pattern of dystrophic epidermolisys bullosa and characterized by severe itching that accompanies the formation of papules, plaques and nodes primarily on the lower limbs skin and imitating prurigo nodularis. Nowadays, less than 100 cases of this disease are reported in the world, thus, the presentation of this clinical case is relevant. Clinical case description. The authors describe the clinical case of pruriginous pattern of dominant dystrophic bullous epidermolysis in 14-year-old female patient. Conclusion. Diagnosis of this disease pattern is extremely difficult and currently all treatment is limited to the symptomatic therapy in order to stop itching and prevent scarring.
About the Authors
Maria A. Leonova
National Medical Research Center of Children’s Health; Pirogov Russian National Research Medical University
Russian Federation
Disclosure of interest:
Russian Federation
MD
eLibrary SPIN: 2858-8196
Lomonosovsky pr-t, 2/62, building 1, Moscow, 119296
Disclosure of interest:
Confirmed the absence of a reportable conflict of interests.
Nikolay N. Murashkin
National Medical Research Center of Children’s Health; Sechenov First Moscow State Medical University; Central State Medical Academy of Department of Presidential Affairs
Russian Federation
Disclosure of interest:
Russian Federation
MD, PhD, Professor
eLibrary SPIN: 5906-9724
Moscow
Disclosure of interest:
Receiving research grants from pharmaceutical companies Jansen, Eli Lilly, Novartis, Abbvi, Pfizer, Amryt Pharma plc. Receiving fees for scientific counseling from companies Galderna, Pierre Fabre, Bayer, Leofarma, Pfizer, AbbVie, Zeldis Pharma.
References
1. Kim WB, Alavi A, Walsh S, et al. Epidermolysis bullosa pruriginosa: a systematic review exploring genotype-phenotype correlation. Am J Clin Dermatol. 2015;16(2):81–87. https://doi.org/10.1007/s40257-015-0119-7
2. Ghosh S, Chaudhuri S, Jain VK. Epidermolysis bullosa pruriginosa: a rare presentation with asymptomatic lesions. Indian J Dermatol Venereol Leprol. 2013;79(2):235–237. https://doi.org/110.4103/0378-6323.107645
3. Kim WB, Alavi A, Pope E, et al. Epidermolysis Bullosa Pruriginosa: Case Series and Review of the Literature. Int J Low Extrem Wounds. 2015;14(2):196–199. https://doi.org/10.1177/1534734615572469
4. Nakamura E, Majima Y, Hashizume H, et al. Dominant dystrophic epidermolysis bullosa pruriginosa with a COL7A1 exon 87 c.6898C>T mutation. Clin Exp Dermatol. 2019;44(1):82–84. https://doi.org/10.1111/ced.13715
5. Loh CC, Kim J, Su JC, et al. Development, reliability, and validity of a novel Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI). J Am Acad Dermatol. 2014;70(1):89–97.e1-e13. https://doi.org/10.1016/j.jaad.2013.09.041
6. Jain SV, Harris AG, Su JC, et al. The Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI): grading disease severity and assessing responsiveness to clinical change in epidermolysis bullosa. J Eur Acad Dermatol Venereol. 2017;31(4):692–698. https://doi.org/10.1111/jdv.13953
7. de Onis M, Onyango AW, Borghi E, et al. Development of a WHO growth reference for school-aged children and adolescents. Bull World Health Organ. 2007;85(9):660–667. https://doi.org/10.2471/blt.07.043497
8. Fine JD, Bruckner-Tuderman L, Eady RA, et al. Inherited epidermolysis bullosa: updated recommendations on diagnosis and classification. J Am Acad Dermatol. 2014;70(6):1103–1126. https://doi.org/10.1016/j.jaad.2014.01.903
9. Vivehanantha S, Carr RA, McGrath JA, et al. Epidermolysis bullosa pruriginosa: a case with prominent histopathologic inflammation. JAMA Dermatol. 2013;149(6):727–731. https://doi.org/10.1001/jamadermatol.2013.155
10. Banky JP, Sheridan AT, Storer EL, et al. Successful treatment of epidermolysis bullosa pruriginosa with topical tacrolimus. Arch Dermatol. 2004;140(7):794–796. https://doi.org/10.1001/archderm.140.7.794
11. Ferreira S, Azevedo A, Velho GC, et al. Epidermolysis Bullosa Pruriginosa successfully treated with concomitant topical and systemic agents. Australas J Dermatol. 2020;61(4):355–357. https://doi.org/10.1111/ajd.13342
12. Ertop P, Vural S, Gökpınar Ili E, et al. Promising effect of intravenous immunoglobulin therapy for epidermolysis bullosa pruriginosa. Int J Dermatol. 2020;59(7):851–855. https://doi.org/10.1111/ijd.14951
13. Zhou AG, Little AJ, Antaya RJ. Epidermolysis bullosa pruriginosa treated with dupilumab. Pediatr Dermatol. 2021;38(2):526–527. https://doi.org/10.1111/pde.14493
14. Shehadeh W, Sarig O, Bar J, et al. Treatment of epidermolysis bullosa pruriginosa-associated pruritus with dupilumab. Br J Dermatol. 2020;182(6):1495–1497. https://doi.org/10.1111/bjd.18855
15. Clawson RC, Duran SF, Pariser RJ. Epidermolysis bullosa pruriginosa responding to dupilumab. JAAD Case Rep. 2021;16:69–71. https://doi.org/10.1016/j.jdcr.2021.07.036
16. Jiang X, Wang H, Lee M, et al. Epidermolysis Bullosa Pruriginosa Treated With Baricitinib. JAMA Dermatol. 2021;157(10):1243–1244. https://doi.org/10.1001/jamadermatol.2021.3174
17. Chen KJ, Fang S, Ye Q, et al. Successful use of tofacitinib in epidermolysis bullosa pruriginosa. Clin Exp Dermatol. 2022;47(3):598–600. https://doi.org/10.1111/ced.14998
18. Kaushik A, Mahajan R, Karim A, et al. Successful use of cyclosporine in epidermolysis bullosa pruriginosa. Dermatol Ther. 2020;33(6):e14489. https://doi.org/10.1111/dth.14489
19. Takahashi T, Mizutani Y, Ito M, et al. Dystrophic epidermolysis bullosa pruriginosa successfully treated with immunosuppressants. J Dermatol. 2016;43(11):1391–1392. https://doi.org/10.1111/1346-8138.13406
20. Ranugha PS, Mohanan S, Chandrashekar L, et al. Epidermolysis bullosa pruriginosa showing good response to low-dose thalidomide — a report of two cases. Dermatol Ther. 2014;27(1):60–63. https://doi.org/10.1111/dth.12047
21. Pallesen KAU, Lindahl KH, Bygum A. Dominant Dystrophic Epidermolysis Bullosa Pruriginosa Responding to Naltrexone Treatment. Acta Derm Venereol. 2019;99(12):1195–1196. https://doi.org/10.2340/00015555-3304
22. Caroppo F, Milan E, Giulioni E, Belloni Fortina A. A case of dystrophic epidermolysis bullosa pruriginosa treated with dupilumab. J Eur Acad Dermatol Venereol. 2022;36(5):e365-e367. https://doi.org/10.1111/jdv.17887
Review
For citations:
Leonova M.A., Murashkin N.N. Pruriginosa Pattern of Dystrophic Epidermolisys Bullosa: Clinical Case. Pediatric pharmacology. 2022;19(6):479-483. (In Russ.) https://doi.org/10.15690/pf.v19i6.2476
Views:
822
Email this article 